Itaspor 130mg Capsule contains Itraconazole, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itaspor is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections. The 130mg dosage form is designed to provide effective plasma concentrations for optimal therapeutic outcomes. Itaspor should be administered orally with food to enhance absorption. Dosage and duration of therapy depend on the type and severity of the infection, and treatment should be guided by clinical response and laboratory findings. Caution is advised in patients with hepatic impairment, as itraconazole is metabolized primarily by the liver. Potential adverse effects include gastrointestinal disturbances, hepatotoxicity, and rare cardiac effects such as congestive heart failure. Drug interactions are significant due to itraconazole’s inhibition of cytochrome P450 3A4 enzymes, necessitating careful review of concomitant medications. Regular monitoring of liver function tests and clinical status is recommended during therapy to ensure safety and efficacy.